Japan's Shionogi to Acquire C&O Pharmaceutical Technology for about $182 Million to expand into China

---

Shionogi takes subtle backdoor into China by acquiring Singapore-listed & Hong Kong-headquartered C&O Pharmaceutical Technology


01 August 2011

"Japan's Shionogi & Co said on Monday that it intends to acquire Hong Kong-headquartered and Singapore-listed China drug-maker C&O Pharmaceutical Technology for about S$219 million."

http://www.biospace.com/news_story.aspx?NewsEntityId=228662

The original news release:

http://www.4-traders.com/SHIONOGI-CO-LTD-6493659/news/SHIONOGI-Co-Ltd-to-Acquire-China-based-C-O-Pharmaceutical-Technology-Holdings-Limited-13733345/

-----------

Dateline -- San Diego, Calif.: 01 August 2011 -- 10:30 PM


Posted by:

David A. Palella
BIOSCIENCE VENTURES Inc.

San Diego, California
cell: 619-787-5767
email:  dpalella@gmail.com
http://www.linkedin.com/in/davidpalella

web site:  http://www.BSVpartners.com

blog: http://biobizdev.blogspot.com


& Group Founder:

Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/

Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/

Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/

& Co-founder:

Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448

---------